PTC\SB\08x (08-03)
Approved for use through 07/31/0006 ONE 0651-0001
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

			Application Number						
			Filing Date						
		TION DISCLOSU	First Named	inventor	Jeffre	y Wilson			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Art Unit	Art Unit				_
				Examiner Na	Examiner Name				_
				Attorney Docket Number			DYOUP0316US		
				U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of of cited D		tee or Applicant ent	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1								

						rigures Appear
	1					
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wis	h to a	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad-	d button. Add
				FOREIGN DAT	TENT DOCUMENTS	Romova

			FORE	IGN PAT	TENT DOCUM	IENTS	Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	75
	1	1058443	EP		2000-12-06			
	2	1259051	EP		2002-11-20			
	3	98/35481	wo		1998-08-13			

	Application Number			
INFORMATION DIOCI COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Jeffre		ey Wilson	
(Not for submission under 37 CFR 1.99)	Art Unit			
(,	Examiner Name			
	Attorney Docket Number		DYOUP0316US	
			_	

	4	01/08430	wo		2001-02-01				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishers.								
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								
*EYAMIN	*EYAMINER: Initial if reference considered, whether or not citation is in conformance with MDEP 609. Draw line through a								

See Kink Codes of USPTO Patent Documents at www.USPTO.000 or MPIP 9616A. * Enter office that issued the document, by the loc-letter code (WIPO Standard ST3.) * For Lapraces patent of counters, the ancidation of the parent for the Empirer or trapreced the sear in Lamber of the patent counter. If which office the Counter to the patent counter of the pa

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date Filing Date Filing Date Filing Date First Number I Justice Wilson Art Unit Examiner Name Attorney Docket Number I DYOUPQ318US

CERTIFICATION STATEMENT

Please see	37.0	FR 1	97	and 1	Q2	to make	the	annrone	iata s	alaction	/el·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Don W. Bulson/	Date (YYYY-MM-DD)	2006-05-22
Name/Print	Don W. Bulson	Registration Number	28192

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superinteed for Commence, P. 0. Bot 1450, Alexandria, V.32.11.450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.